about
Inflammatory breast cancer: clinical progress and the main problems that must be addressedRetrospective review of male breast cancer patients: analysis of tamoxifen-related side-effectsBreast carcinoma in men: a population-based studyESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registriesSurgeon influence on use of needle biopsy in patients with breast cancer: a national medicare study.Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.Comparative effectiveness research in cancer with observational data.Limits of observational data in determining outcomes from cancer therapy.Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle.Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?Completion of adjuvant radiation therapy among women with breast cancer.Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based reviewAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.A method to predict breast cancer stage using Medicare claims.Use of intravenous bisphosphonates in older women with breast cancerOpen-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States.Rates of BRCA1/2 mutation testing among young survivors of breast cancerFirst do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare.Is breast cancer survival improving?Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused updateBreast cancer version 3.2014.Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer.Breast cancer in men.Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.Problems in transition and quality of care: perspectives of breast cancer survivors.Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER databasePhysician variation in management of low-risk prostate cancer: a population-based cohort studyUpdate on locally advanced breast cancer.Variation in Intensity and Costs of Care by Payer and Race for Patients Dying of Cancer in Texas: An Analysis of Registry-linked Medicaid, Medicare, and Dually Eligible Claims Data.The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.Impact of a scientific presentation on community treatment patterns for primary breast cancer.Risk of cardiac death after adjuvant radiotherapy for breast cancerDeterminants of practice patterns and quality gaps in lung cancer staging and diagnosisQuality gaps and comparative effectiveness in lung cancer staging and diagnosis.
P50
Q21195182-A53FD707-D257-47F6-813D-1C0868232F04Q27024138-B72739B5-C114-4464-907D-20D4F3C07AD8Q28268948-85C16D5E-A3B6-4C83-8FB2-F793EC7A9947Q30317067-5833C928-334E-4453-A729-87504B121172Q30557544-48881393-A3FA-4A37-9A1C-BEE96D881F13Q30587015-6CDE8109-F565-4250-AD03-C165C95D9CB1Q30814798-FEA6FB35-9864-4D94-8B33-CC556AB52789Q30955412-ED4C5E91-12DF-4947-BC0A-9B4AC9EE0956Q31153256-0B902603-8F53-4399-B1AE-C4D745667607Q31155248-611D8538-7E92-4F5F-81D8-975E99842F1BQ33351366-ACCD218F-6436-4BB9-850C-76EAB4568A4CQ33553921-37281077-FB54-4481-9F11-F8D7A2288627Q33554036-97508F66-05E8-46F7-8BB6-E8C4D8E80100Q33561966-C8B9CCC9-F355-4F61-A4C0-7CEE3790859FQ33631047-DD9F1D93-245F-44CA-8B30-6C5DA398BF5DQ33638696-89C46857-B67E-461E-8BE3-8D41EFE98692Q33666930-6FEC7FFD-48CE-4D26-9EA7-B1F09CDBA41DQ33683126-3DD48523-E300-401C-903D-A3254BDA9EF5Q33890507-CE8AD2F8-E1B5-49A5-8A59-9D4E9490C70AQ33923031-8FB3748D-7984-4DA3-819C-86774CC41C52Q34104204-CF1A049E-EF23-465B-BBB4-EDD400FBDA53Q34184798-50A0C02C-6963-45EA-A92D-F4D7CF602590Q34197501-8181447F-E2C4-4DA7-9A08-9B196ACD4566Q34198900-D7B646E2-6A09-4286-86F6-2CC5F03D9A55Q34285880-8D4CFD67-39B0-4E20-83F5-4F14E31DC9AAQ34421634-D0B269A4-82C0-4041-98EC-A5C48BAF11FAQ34661225-21923259-B280-432F-82AB-A224AAAF707AQ34815323-E95CBB3D-7F40-4B8A-B717-44C93CFCC6F2Q34962018-57C42BA5-F300-45C6-A590-CCE48FD4BDE9Q34984314-191FC472-554F-4F97-9AA3-A6FDC1BCA2C3Q35012516-F5A8BF44-67B5-4A24-8B2A-CD005E36D0A8Q35073254-79016DF8-10BF-48EE-B3EF-A40686307A54Q35213290-3FE46444-8D39-4ADE-8BCC-A4B290422274Q35600951-4319315B-7A38-491F-A1A5-65DE58E86BF2Q35661690-B196D11C-C33F-4549-A94A-743D87928064Q35750336-73D296A1-BA96-4D95-A6FF-D8F02A2127EAQ35754000-6A8F9279-94D2-4F21-9332-205A1C1BBA83Q35754003-BF012DC5-515A-4C5E-93E9-0F168FA8BD10Q35852897-82028166-288E-42B6-97D7-95A3D39ADC52Q35852907-13FF9F0E-3BDB-4AB9-B538-ABBEFB2AE7D1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sharon H Giordano
@nl
Sharon H Giordano
@sl
Sharon H. Giordano
@en
Sharon H. Giordano
@es
type
label
Sharon H Giordano
@nl
Sharon H Giordano
@sl
Sharon H. Giordano
@en
Sharon H. Giordano
@es
prefLabel
Sharon H Giordano
@nl
Sharon H Giordano
@sl
Sharon H. Giordano
@en
Sharon H. Giordano
@es
P106
P1153
23990515600
P21
P31
P496
0000-0002-8700-2767